Heimo Stroissnig

Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam.

Thaddeus P. Pruss, Heimo Stroissnig, S Radhofer-Welte et al. · PubMed · 1990 · 52 citations

Medicine, Pharmacokinetics, Pharmacology +16

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

Steven R. Feldman, Nataliya Reznichenko, Grażyna Pulka et al. · BioDrugs · 2021 · 31 citations · Full text

Life Sciences, Clinical Sciences, Pharmacotherapy +15

Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis

Steven R. Feldman, Nataliya Reznichenko, Fausto Berti et al. · Expert Opinion on Biological Therapy · 2023 · 28 citations · Full text

Medicine, Dermatology, Pharmacology +14

Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue

Thijs van Iersel, Heimo Stroissnig, Peter Giesen et al. · Thrombosis and Haemostasis · 2010 · 27 citations

Medicine, Pharmacokinetics, Pharmacology +14

A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults

Christopher Wynne, Paul Hamilton, Kristi McLendon et al. · Expert Opinion on Investigational Drugs · 2023 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14